Johann de Bono

Johann de Bono

UNVERIFIED PROFILE

Are you Johann de Bono?   Register this Author

Register author
Johann de Bono

Johann de Bono

Publications by authors named "Johann de Bono"

Are you Johann de Bono?   Register this Author

100Publications

2932Reads

28Profile Views

PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.

Eur Urol 2019 Oct 4;76(4):459-460. Epub 2019 Apr 4.

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.029DOI Listing
October 2019

Genetic Analysis of Circulating Tumour Cells.

Recent Results Cancer Res 2020 ;215:57-76

The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-26439-0_3DOI Listing
October 2019

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Eur Urol 2019 Sep 19;76(3):306-312. Epub 2018 Nov 19.

Chris O'Brien Lifehouse, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; University of NSW, Sydney, Australia; University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.11.001DOI Listing
September 2019

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

N Engl J Med 2019 Sep 30. Epub 2019 Sep 30.

From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911206DOI Listing
September 2019

Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art.

Radiology 2019 Aug 25;292(2):273-286. Epub 2019 Jun 25.

From the Radiomics Group, Vall D'Hebron Institute of Oncology, Barcelona, Spain (R.P.L.); Departments of Radiology (N.T., D.M.K.) and Nuclear Medicine (W.J.G.O.), Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, England; Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, England (A.R.P.); Divisions of Radiotherapy and Imaging (W.J.G.O., D.M.K.) and Clinical Studies & Prostate Cancer Targeted Therapy Group (J.d.B.), Institute of Cancer Research, Sutton, England; Departments of Radiology (S.F.) and Genitourinary Oncology Service and Medicine (M.J.M.), Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (H.A.V., A.O.); Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland (H.A.V., A.O.); and Department of Medicine, Weill Cornell Medicine, New York, NY (M.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019181931DOI Listing
August 2019

Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.

J Clin Oncol 2019 Aug 2;37(24):2182-2184. Epub 2019 Jul 2.

Adam Sharp, MD, PhD, The Institute of Cancer Research; The Royal Marsden, London, United Kingdom; Nuria Porta, PhD; Maryou B.K. Lambros, MPhil; and Jonathan C. Welti, PhD, The Institute of Cancer Research, London, United Kingdom; Alec Paschalis, MD, The Institute of Cancer Research; The Royal Marsden, London, United Kingdom; Ganesh V. Raj, MD, PhD, The University of Texas Southwestern Medical Center, Dallas, TX; Stephen P. Plymate, MD, University of Washington; VA Puget Sound Health Care System Geriatric Research Education and Clinical Center, Seattle, WA; and Johann S. de Bono, MD, PhD, The Institute of Cancer Research; The Royal Marsden, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01104DOI Listing
August 2019

Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.

Cell Rep 2019 Aug;28(8):2156-2168.e5

Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Faculty of Medicine, Università della Svizzera Italiana, 1011 Lugano, Switzerland; Department of Medicine, University of Padua, 35131 Padua, Italy; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.07.068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715643PMC
August 2019

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Eur Urol 2019 02 14;75(2):285-293. Epub 2018 Aug 14.

The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.07.035DOI Listing
February 2019

Immunotherapy for lethal prostate cancer.

Nat Rev Urol 2019 02;16(2):69-70

Division of Clinical Studies, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0121-yDOI Listing
February 2019

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Mol Cell 2019 01 6;73(1):22-35.e6. Epub 2018 Dec 6.

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Department of Urology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA; Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10972765183089
Publisher Site
http://dx.doi.org/10.1016/j.molcel.2018.10.034DOI Listing
January 2019

Health economic impact of liquid biopsies in cancer management.

Expert Rev Pharmacoecon Outcomes Res 2018 Dec 7;18(6):593-599. Epub 2018 Aug 7.

e Department of Medical Cell Biophysics , University of Twente , Enschede , the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737167.2018.1505505DOI Listing
December 2018

Alternative splicing in prostate cancer.

Nat Rev Clin Oncol 2018 11;15(11):663-675

The Institute for Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0085-0DOI Listing
November 2018

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Eur J Cancer 2018 11 10;104:32-38. Epub 2018 Oct 10.

The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, SM2 5PT, London, UK; The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049183133
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2018.08.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259582PMC
November 2018

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Eur Urol Oncol 2018 Nov 30. Epub 2018 Nov 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.006DOI Listing
November 2018

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.

Cancers (Basel) 2018 Oct 31;10(11). Epub 2018 Oct 31.

Department of Medical Cell BioPhysics, University of Twente, 7522 NH Enschede, The Netherlands.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/10/11/416
Publisher Site
http://dx.doi.org/10.3390/cancers10110416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266016PMC
October 2018

Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.

Curr Opin Support Palliat Care 2018 09;12(3):339-343

The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0000000000000358DOI Listing
September 2018

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

J Neurooncol 2018 Aug 10;139(1):107-116. Epub 2018 Apr 10.

Drug Development Unit, The Royal Marsden Hospital Trust and Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2847-zDOI Listing
August 2018

Hypoxia and Noncoding RNAs in Taxane Resistance.

Trends Pharmacol Sci 2018 08 8;39(8):695-709. Epub 2018 Jun 8.

School of Life Health and Chemical Sciences, The Open University, Milton Keynes, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2018.05.002DOI Listing
August 2018

Reply to C. Ren et al.

J Clin Oncol 2018 08 12;36(22):2354-2356. Epub 2018 Jun 12.

Glenn Heller, Memorial Sloan Kettering Cancer Center, New York, NY; Robert McCormack and Thian Kheoh, Janssen Research & Development, Raritan, NJ; Arturo Molina, Janssen Research & Development, Los Angeles, CA; Matthew R. Smith, Massachusetts General Hospital, Boston, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, Netherlands; Dana T. Aftab, Exelixis, South San Francisco, CA; Mohammed Hirmand, Medivation, San Francisco, CA; Ana Limon-Carrera, Takeda Oncology, Cambridge, MA; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; Martin Fleisher, Memorial Sloan Kettering Cancer Center, New York, NY; Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and Howard I. Scher, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2672DOI Listing
August 2018

Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.

Cold Spring Harb Perspect Med 2018 06 1;8(6). Epub 2018 Jun 1.

Division of Clinical Studies, The Institute of Cancer Research, Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a030635DOI Listing
June 2018

Second-generation antiandrogens in nonmetastatic CRPC.

Nat Rev Urol 2018 Jun;15(6):342-344

Division of Clinical Studies, The Institute of Cancer Research, Sutton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0007-zDOI Listing
June 2018

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Cell 2018 06;173(7):1770-1782.e14

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.04.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084431PMC
June 2018

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

Eur J Cancer 2018 05 31;95:20-29. Epub 2018 Mar 31.

Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK; Gynaecology Unit, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296443PMC
May 2018

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Nat Genet 2018 05 16;50(5):682-692. Epub 2018 Apr 16.

The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41588-018-0086-z
Publisher Site
http://dx.doi.org/10.1038/s41588-018-0086-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372064PMC
May 2018

Metastatic Prostate Cancer.

N Engl J Med 2018 04;378(17):1653-1654

Institute of Cancer Research, London, United Kingdom

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1803343DOI Listing
April 2018

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Eur Urol Focus 2018 03 10;4(2):235-244. Epub 2016 Oct 10.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.09.005DOI Listing
March 2018

Reply to M. Horiguchi et al.

J Clin Oncol 2018 03 26;36(8):826-827. Epub 2018 Jan 26.

Mario A. Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wenping Zhang, Sanofi, Bridgewater, NJ; Zhenming Shun, Sanofi, Cambridge, MA; and Johann de Bono, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.3748DOI Listing
March 2018

Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.

Eur Urol 2018 02 30;73(2):e32-e33. Epub 2017 Aug 30.

Department Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Department of Oncology, University of Bern, Bern, Switzerland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.08.014DOI Listing
February 2018

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

J Clin Oncol 2018 02 22;36(6):572-580. Epub 2017 Dec 22.

Glenn Heller, Martin Fleisher, and Howard I. Scher, Memorial Sloan Kettering Cancer Center; Howard I. Scher, Weill Cornell Medical College, New York, NY; Robert McCormack, Janssen Research & Development, Raritan, NJ; Thian Kheoh and Arturo Molina, Janssen Research & Development, Los Angeles; Dana T. Aftab, Exelixis, South San Francisco; Mohammad Hirmand, Medivation, San Francisco, CA; Matthew R. Smith, Massachusetts General Hospital, Boston; Ana Limon, Takeda Oncology, Cambridge, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, the Netherlands; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; and Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815402PMC
February 2018

Metastatic Prostate Cancer.

N Engl J Med 2018 02 7;378(7):645-657. Epub 2018 Feb 7.

From Tulane Medical School, New Orleans (O.S.); and the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London (J.S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1701695DOI Listing
February 2018

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

Cell Rep 2018 01;22(3):796-808

Department of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.12.078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843368PMC
January 2018

Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.

Value Health 2017 12 11;20(10):1411-1419. Epub 2017 Jul 11.

Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10983015173027
Publisher Site
http://dx.doi.org/10.1016/j.jval.2017.05.024DOI Listing
December 2017

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m) and the Currently Approved Dose (25 mg/m) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

J Clin Oncol 2017 Oct 15;35(28):3198-3206. Epub 2017 Aug 15.

Mario Eisenberger, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Anne-Claire Hardy-Bessard, Centre Armoricain d'Oncologie, Centre Armoricain de Radiothérapie, d'Imagerie Médicale et d'Oncologie-Hôpital Privé Des Côtes d'Armor, Plérin; Loïc Mourey, Institut Claudius Regaud, l'Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Mustapha Chadjaa, Sanofi, Vitry-sur-Seine, France; Choung Soo Kim, Asan Medical Center, Seoul, South Korea; Lajos Géczi, National Institute of Oncology, Budapest, Hungary; Daniel Ford, City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham; Johann de Bono, Prostate Cancer Targeted Therapy Team, Royal Marsden National Health Service Foundation Trust/The Institute of Cancer Research, Sutton, United Kingdom; Joan Carles, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Phillip Parente, Eastern Health Clinical School, Monash University, Box Hill Hospital, Melbourne, Victoria, Australia; Albert Font, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Gabriel Kacso, Iuliu Hatieganu Medical University, Amethyst Radiology Therapeutic Center, Cluj, Romania; Wenping Zhang, Sanofi, Bridgewater, NJ; and John Bernard, Sanofi, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1076DOI Listing
October 2017

Abiraterone in Metastatic Prostate Cancer.

N Engl J Med 2017 10;377(17):1694-5

Tulane University School of Medicine, New Orleans, LA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1711029DOI Listing
October 2017

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses.

Br J Cancer 2017 Sep 22;117(7):954-964. Epub 2017 Aug 22.

Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625678PMC
September 2017

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Lung Cancer 2017 09 15;111:6-11. Epub 2017 Jun 15.

Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.06.005DOI Listing
September 2017

Rationale for Modernising Imaging in Advanced Prostate Cancer.

Eur Urol Focus 2017 04 15;3(2-3):223-239. Epub 2016 Jul 15.

Drug Development Unit, Institute of Cancer Research and the Royal Marsden NHS Trust, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.06.018DOI Listing
April 2017

The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.

Trends Cancer 2016 11 23;2(11):646-656. Epub 2016 Nov 23.

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Drive, Room 5W458, MSC 9739, Bethesda, MD 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527674PMC
November 2016